Although constitutive activation of RAS-RAF-MAPK pathway occurs in a majority of advanced prostate tumors, the incidence of direct mutations of the upstream activators such as KRAS and BRAF are not commonly found in prostate cancer [31]. The gene discussed is BRAF; the disease is prostate carcinoma.